

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.64 Billion in January,

保瑞公告 1 月自結合併營收新台幣 16 億 4 仟萬元

Taipei, Taiwan, February 10, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for January 2025 reached NT\$1.64 billion, reflecting a 33.59% increase YoY.

台北，台灣，2025 年 2 月 10 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 1 月自結合併營收為新台幣 16 億 4 仟萬元，年增 33.59%。

During the month, the Company saw increased momentum in tech transfer of new clients and mass production orders within our CDMO segment, particularly from our sterile injection site in Maryland. However, this growth was partially offset by fewer working days in Taiwan, with our Zhunan facility experiencing the most impact. Looking ahead, we expect to accelerate the on boarding process in February and remain on track to meet target submission schedules for new clients. Factoring in the timing of Chinese New Year in 2024, January CDMO net revenues already achieved >60% of the combined January and February revenue from the previous year.

保瑞的 CDMO 業務領域在 2025 年伊始就迎來多起新客戶技轉與量產專案，馬里蘭州無菌注射廠的表現突出，然因台灣工作天數較少對竹南廠業務產生一定影響，公司預期於 2 月繼續加速完成新客戶技轉與導入進程，確保達成客戶的目標送件時程。考量去年的春節時間點較晚，CDMO 業務 1 月的合併營收已達成去年 1 至 2 月合併營收的 6 成以上，表現不俗。

In our commercial business, the Company continued to see steady market share expansion in our specialty pharmaceutical segment in the United States, with momentum expected to accelerate sequentially. While certain products have faced competition and price volatility, we believe that disciplined execution of new product launches—such as Deflazacort—will support margin expansion and enhance our product mix in 2025, with benefits extending into mid-term.

美國市場藥物銷售部分，保瑞持續擴展在特殊藥局專科通路的市佔率，預期這一成長動能將逐季增溫。儘管部分產品面臨市場競爭與價格波動，我們相信公司持續穩健地執行新產品上市計劃（例如用於肌肉失養症 Deflazacort）將有助於優化產品組合，推動今年與中長期的成長。

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracorpcdmo.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以 Making Success More Certain 為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracorpcdmo.com>

Investor/Media enquiries

Nadiya Chen, Investor Relations

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com

新聞聯繫人：

投資人關係 陳菽雅

電話：(02) 2790-1555 #9108

Email : Nadiya.Chen@bora-corp.com